5Y Capital

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Epigenic Therapeutics is a biotech firm that offers gene editing therapy.

METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.

GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.

ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs.

Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.

METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.

Zhongke Guosheng is a bio-based materials R&D firm that designs and develops furan-based bio-based materials.

Geneoscopy, LLC is a diagnostic company based in Saint Louis, Missouri, focused on developing non-invasive solutions for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, Geneoscopy utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel aimed at identifying colorectal cancer by detecting the effects of cancer-related DNA mutations. The company is committed to improving colorectal cancer screening compliance and facilitating early detection, thereby reducing the associated morbidity and mortality. By employing a novel methodology to extract human RNA transcripts from stool samples, Geneoscopy aims to provide a reliable alternative to traditional colonoscopies, which are often viewed as unpleasant and invasive. In addition to its colorectal cancer diagnostic test, Geneoscopy is also exploring other potential applications of its RNA technology for additional gastrointestinal conditions.

DeepCure Inc. offers drugs discovery services using artificial intelligence technology. Its products include De-novo Lead Discovery, Artificial Intelligence-driven Lead Optimization, and MoIDB. De-novo Lead Discovery uses artificial intelligence algorithms to analyze drug candidates from virtual library. Artificial Intelligence-driven Lead Optimization identifies optimization steps to improve the development of drugs. MolDB is designed to maximize scale, diversity, and synthesizability of chemical search space. DeepCure Inc. develops new drug through molecular feature extraction, MoIDB, artificial intelligence predictive modeling and feedback loop. The company was founded in 2018 and is based in Boston, Massachusetts.

Robigo specializes in biopesticide development by engineering the plant microbiome to enhance crop health and mitigate diseases. The company focuses on creating precision microbial treatments that not only improve plant vitality but also help recover lost agricultural yields. Utilizing advanced microbial engineering and data science, Robigo's products are designed to be effective while ensuring safety for beneficial microbes, pollinators, humans, and the broader environment. This approach enables farmers to boost their productivity and profitability while promoting sustainable farming practices.

Axbio Inc. is a biotechnology company based in Shenzhen, China, specializing in the development and manufacturing of advanced genetic sequencing technology and diagnostic equipment. Founded in 2016, the company offers a variety of genome extraction kits, including those for stool, blood, saliva, and bacteria. Axbio's product line also encompasses sequencing and diagnostic systems, disposable biochips, and reagents. The company employs semiconductor nanotechnology in its biochips for rapid molecular in-vitro diagnostics and utilizes a microfluidic Bio-CMOS platform for high-throughput sequencing. Axbio's capabilities extend from low-cost handheld devices for bedside diagnostics to fully automated instruments suitable for independent laboratories and hospitals, facilitating services such as early cancer screening, rapid pathogen detection, and drug development. The company is currently operating in stealth mode.

Developer of biocomputing technology. The company develops synthetic biology platform to improve the efficiency of biotech R&D, making biological product development as simple and efficient as software development.

Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.

Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

SemiosBio Technologies Inc. offers innovative pest management solutions for growers of tree fruits, nuts, and grapes globally. The company has developed the Semios platform, which enables real-time monitoring and control of agricultural operations through a comprehensive network of sensors. This platform provides continuous coverage and includes features such as automated pheromones, pest traps, and pest pressure notifications, along with frost monitoring and alerts. Additionally, it evaluates disease risk, monitors irrigation, and assesses soil conditions, helping growers make informed decisions to optimize crop quality while reducing agricultural inputs. Founded in 2009 and headquartered in Vancouver, Canada, Semios also operates locations in Fresno, California; Wenatchee, Washington; and Heerlen, the Netherlands.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Etern is developing small molecule innovative drugs for oncology therapies.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Fount Bio is a life science company that applies proprietary advances in glycopolymer research for skin health. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts, United States.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.

AliveX is a developer of an AI-driven immunology platform that focuses on biomarker discovery for early cancer screening, precision medicine, and treatment monitoring. By integrating multi-omics data, artificial intelligence, and computational biology, the platform aims to decode the human immune system. This innovative approach enables collaboration with leading clinicians, research institutions, and pharmaceutical companies to address significant clinical challenges. AliveX's efforts are directed towards transforming life sciences research and advancing the next generation of precision diagnostics and treatments in the field of immunology.

Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.

Revolo Biotherapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and immunological diseases, such as asthma, atopic dermatitis, and inflammatory bowel disease. The company's approach is grounded in the natural mechanisms employed by Mycobacterium tuberculosis to evade the host immune system, allowing it to suppress inflammatory responses. Unlike existing treatments that aim to suppress the immune system and often require chronic dosing with significant side effects, Revolo's immune-resetting therapies have shown promise in preclinical and human studies by safely transitioning the immune system from a pro-inflammatory state to a regulatory one. This novel strategy aims to induce long-term disease remission without the adverse effects typically associated with conventional therapies. Founded in 2001 and based in London, Revolo Biotherapeutics is dedicated to transforming the treatment landscape for patients suffering from allergic and immune-mediated conditions.

Galixir is an artificial intelligence technology to promote the research and development of new drugs. Our artificial intelligence drug discovery platform can help drug research and development scientists greatly save time and cost in drug development. At the same time, our platform also provides comprehensive patent protection coverage for the drugs developed. Relying on cutting-edge artificial intelligence technology, Xingyao combines engineering chemistry, computational chemistry, computational biology, and cloud computing technologies to serve the various processes of drug development.

Vesigen, Inc. is a biotechnology company focused on developing innovative therapeutic products that utilize extracellular vesicle delivery technology to target intracellular sites. Founded in 2020 and based in Cambridge, Massachusetts, the company employs its proprietary ARMMs technology to facilitate the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This approach aims to overcome the challenges associated with intracellular drug delivery, thereby broadening the range of potential druggable targets and enabling the creation of novel treatments for various diseases. Vesigen's mission is to address unmet medical needs through its advanced therapeutic solutions.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to developing therapies for diseases associated with mitochondrial dysfunction, which includes both rare genetic disorders and common age-related conditions. The company's lead product candidate, Elamipretide, aims to address these health issues, while additional candidates like SBT-20 and SBT-272 are being explored for their potential benefits in stabilizing mitochondrial function and treating neurodegenerative diseases, respectively. Founded in 2006 and based in George Town, Cayman Islands, Stealth BioTherapeutics collaborates with patients and advocacy groups to deepen its understanding of the challenges faced by those with mitochondrial diseases and to raise awareness of their therapeutic programs.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

SemiosBio Technologies Inc. offers innovative pest management solutions for growers of tree fruits, nuts, and grapes globally. The company has developed the Semios platform, which enables real-time monitoring and control of agricultural operations through a comprehensive network of sensors. This platform provides continuous coverage and includes features such as automated pheromones, pest traps, and pest pressure notifications, along with frost monitoring and alerts. Additionally, it evaluates disease risk, monitors irrigation, and assesses soil conditions, helping growers make informed decisions to optimize crop quality while reducing agricultural inputs. Founded in 2009 and headquartered in Vancouver, Canada, Semios also operates locations in Fresno, California; Wenatchee, Washington; and Heerlen, the Netherlands.

Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.

Adjuvance Technologies, Inc. is a biopharmaceutical company based in Lincoln, Nebraska, founded in 2009. The company specializes in the design and manufacture of adjuvant molecule vaccines, which enhance the immune response in vaccination. Its product offerings include Saponex, a synthetic version of the naturally occurring adjuvant QS-21; TQL1055, a synthesized novel analogue; and Triterpene Saponin Synthesis Technology (TriSST), which focuses on the synthesis of novel compositions. Additionally, Adjuvance provides TiterQuil, a collection of unique molecules that do not occur in nature. Through its innovative approach, Adjuvance Technologies aims to advance vaccine efficacy and contribute to public health.

Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.

Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.

IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.

ZielBio, Inc. is a biotechnology company focused on identifying high-value disease targets and developing therapeutic interventions to enhance patient outcomes. The company is based in Charlottesville, Virginia, and utilizes its proprietary drug discovery platform, Zielfind, which integrates functional high-throughput screening with large content data analytics to pinpoint valuable targets. ZielBio's lead compound, ZB131, is a humanized monoclonal antibody designed to target cell surface plectin, a significant player in various cancers including ovarian, pancreatic, lung, and colorectal cancer. Founded in 2010, ZielBio aims to transform disease treatment through innovative therapeutic approaches.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients with autoimmune diseases and cancers. Established in 2009, the company is known for its lead product, annexuzlimab, a monoclonal antibody designed to address various autoimmune conditions. MedAnnex aims to create first-in-class antibody therapies that significantly enhance the quality of life for individuals affected by these serious health issues. Through its research and development efforts, the company is committed to advancing therapeutic options in the biotechnology sector.

Xbiome Co. Ltd. is an AI-based microbiome drug development company founded in 2017 and headquartered in Shenzhen, China. It focuses on intestinal micro-ecology and aims to enhance gut health for a population of 1.3 billion people. By leveraging artificial intelligence, Xbiome analyzes the gut flora of patients and donors, enabling the efficient development of targeted pharmaceuticals for micro-ecological treatment. This innovative approach positions Xbiome as a leader in the application of AI technology within the pharmaceutical industry in China.

Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.

Apic Bio, Inc. is a biotechnology company focused on developing gene therapies for rare and complex neurological and liver diseases. Founded in 2017 and based in Cambridge, Massachusetts, the company specializes in treating conditions such as alpha-1 antitrypsin deficiency. Apic Bio utilizes a gene therapy platform that employs a Dual Function Vector (df-AAV) to simultaneously silence the Z-AAT protein and enhance the M-AAT protein in the liver. This innovative approach aims to address the challenges of genetic diseases through targeted therapies, providing hope for patients with undertreated conditions.

Retrotope Inc. is a biotechnology company that focuses on developing drugs for the treatment of degenerative and intractable diseases, particularly neurological disorders. Based in Los Altos, California, the company aims to preserve and restore mitochondrial health through a novel drug platform that targets metabolic processes linked to oxidative stress. Retrotope's portfolio includes RT001, a drug designed for infantile neuroaxonal dystrophy, and it actively works on treatments for conditions such as Parkinson's disease, Alzheimer's disease, mitochondrial myopathies, and retinopathies. Established in 2006, Retrotope employs innovative approaches, including the isotope effect, to slow damaging biological pathways, thereby addressing various major classes of biopolymers and advancing its commitment to improving patient outcomes in degenerative diseases.

Xgene Pharmaceutical Inc. is a pharmaceutical company founded in 2015 and based in the Cayman Islands. The company specializes in the development of small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Through its research and development efforts, Xgene Pharmaceutical seeks to address significant medical needs in these areas.

GeneDock, founded in September 2014, is a national high-tech enterprise specializing in precision medical data technology. The company develops and provides a comprehensive SaaS platform that allows users to extract, analyze, and visualize medical records, facilitating improved research and studies for medical and scientific institutions. With industry-leading expertise, GeneDock has successfully built data platforms for numerous prominent facilities, including top three hospitals and leading industry organizations in China. The core team comprises members with backgrounds from renowned companies, and the firm has attracted investment from notable institutions. GeneDock aims to drive innovation in healthcare through advanced data technology solutions.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.

Vigeo Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutic agents for treating advanced malignant tumors. Established in 2011, the company is working on a first-in-class drug discovery pipeline aimed at reprogramming the tumor immune microenvironment (TIME). Its lead anti-cancer agent is a peptide fragment derived from the prosaposin protein, which inhibits metastasis and tumor growth by promoting the production of an inhibitory molecule within the tumor microenvironment. Vigeo Therapeutics plans to initiate multiple combination studies to assess the efficacy of its lead product, VT1021, in conjunction with various chemotherapies and anti-PD-1 antibodies, with the goal of improving treatment options for patients with multiple types of cancer.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.

Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.

Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.

InSilixa, Inc., headquartered in Sunnyvale, CA, is a multidisciplinary, highly motivated and highly technical team comprised of industry veterans with diverse backgrounds in semiconductor, biotechnology, medicine, and informatics. Founded in 2012, InSilixa is driven by the quest to democratize and drive down the cost of molecular diagnostics worldwide by leveraging its proprietary semiconductor-based CMOS biochip technology. To that end, the company is developing point-of-care (PoC) and near patient platforms for the delivery of low cost, high-performance, and mass-deployable solutions for DNA and protein-based diagnostic testing.

DNAtrix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in virus-driven immunotherapies for cancer treatment. The company develops modified viruses designed to selectively target and kill cancer cells, with its lead product, DNX-2401, focused on glioblastoma, an aggressive and currently incurable brain tumor. This oncolytic immunotherapy has shown promising early results, having been administered to over 35 patients. In addition to DNX-2401, DNAtrix is advancing other therapies, including DNX-2440 and DNX-2450 for solid tumors, and MYX-135 for hematological malignancies. The company aims to expand its platform technology to address a broader range of cancers, including brain metastases, ovarian, and pancreatic cancer. DNAtrix has formed a strategic partnership with Valo Therapeutics to enhance its research and development efforts.

Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.

Senhwa Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2012 and headquartered in New Taipei City, Taiwan, the company is advancing several drug candidates through clinical trials. Notably, CX-4945 is undergoing phase I/II trials for cholangiocarcinoma in combination with gemcitabine and cisplatin, while CX-5461 is being tested in phase I studies for advanced hematologic malignancies and solid tumors, including breast cancer. Additionally, CX-4945 is involved in trials for advanced basal cell carcinoma and recurrent SHH medulloblastoma through pediatric brain tumor consortium studies. Senhwa Biosciences aims to identify and develop therapies that have the potential to significantly enhance treatment outcomes for patients, focusing on underexploited targets that could improve the standard of care.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing individualized immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary Arcelis technology platform, the company aimed to create personalized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. Argos also explored therapies for transplant rejection and autoimmune diseases, with products in various stages of development targeting conditions such as lupus and other inflammatory disorders. Founded in 1997, the company was previously known as Merix Bioscience, Inc. However, Argos Therapeutics ceased operations and filed for Chapter 7 bankruptcy on September 24, 2019.

Envisia Therapeutics Inc. is a biotechnology company dedicated to discovering and developing innovative therapies for ocular conditions. Founded in 2013 and based in Durham, North Carolina, the company addresses significant unmet medical needs in ophthalmology, particularly for conditions like glaucoma. Envisia's lead product, ENV515, is a prostaglandin analogue formulated with a biodegradable PRINT particle technology, designed to provide sustained intraocular pressure reduction over several months. The company's research and development efforts focus on overcoming barriers associated with traditional ocular therapies, such as poor drug uptake and systemic side effects, by utilizing biocompatible polymers and extended-release delivery systems. With an increasing demand for effective ocular therapeutics due to a rapidly aging population, Envisia aims to significantly improve patient outcomes and adherence to treatment protocols in the field of eye care.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.

Oxyrane UK Limited, a biopharmaceutical company, develops novel and biosuperior enzyme replacement therapies for the treatment of lysosomal storage diseases. It provides human lysosomal enzymes that enable clinically effective enzyme uptake and localization using its glycoengineered yeast platform. The company was founded in 2006 and is based in Manchester, United Kingdom. It has locations in Gent, Belgium; and Burlington, Massachusetts.

Kindstar Global (Beijing) Technology, Inc. is a Chinese provider of specialty clinical testing services, primarily serving hospitals across the country, including tertiary care facilities. Founded in 2003 and headquartered in Wuhan, the company specializes in esoteric diagnostic testing and laboratory services. It also offers medical research, clinical trial services, and translational medicine studies to healthcare professionals and pharmaceutical companies. Kindstar Global is committed to developing advanced medical testing technologies and adheres to international standards and guidelines. The company operates laboratory facilities in major cities such as Beijing, Shanghai, and Wuhan, and maintains strategic partnerships, including one with ImmunArray, to enhance its service offerings.

Indel Therapeutics Inc. is a Vancouver‐based biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance. The Company has a growing pipeline of novel antibiotic drug discovery programs focused on curing difficult‐to‐treat and hospital‐acquired infections. These programs are based on Indel's paradigm‐changing antimicrobial drug discovery platform, a patented technology that that has opened a rich, new area of antimicrobial drug targets for the treatment of infectious diseases and has the potential to provide an advantage against drug resistance.

Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.

OriGene Technologies, Inc. specializes in the development, manufacturing, and sale of genome-wide research and diagnostic products tailored for academic, pharmaceutical, and biotechnology applications. Founded with a focus on creating a comprehensive collection of full-length human cDNAs, the company offers a diverse range of products, including cDNA clones, shRNA and siRNA tools, and CRISPR/Cas9 genome editing products. Additionally, OriGene provides proteins and lysates, an extensive array of antibodies for immunohistochemistry, and various assay kits, including ELISA and luminex kits. The company supports critical biological research by supplying essential resources for cancer biomarker studies, stem cell research, and other areas. With a commitment to facilitating gene-based research, OriGene distributes its products globally through distributors and online channels. Established in 1995 and based in Rockville, Maryland, OriGene continues to enhance its offerings to meet the evolving needs of researchers in the life sciences field.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.

Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Green Biologics Limited is an industrial biotechnology company based in Abingdon, United Kingdom, focused on producing renewable specialty chemicals. The company offers products such as n-butanol, acetone, and C4 derivatives, along with GreenFlame charcoal lighting fluids. These products find applications in various sectors, including paints, coatings, adhesives, personal care, cosmetics, food ingredients, health, and industrial cleaners. Green Biologics aims to be a leader in advanced fermentation technologies that convert biomass into renewable fuels and chemicals. Established in 2002, the company has additional facilities in the United States and satellite offices in China, Brazil, and India.

HD Biosciences Inc. is a Shanghai-based biotechnology company that specializes in contract research for drug discovery. The company has developed a comprehensive range of technology platforms and expertise in areas such as assay development, high throughput drug screening, structure-activity relationship (SAR) studies, and hit-to-lead biology solutions. Additionally, it focuses on natural product-based lead discovery. HD Biosciences has established long-term research agreements with notable clients, including Pfizer and Organon, positioning itself as a leader in biology-based drug discovery in China. Its services encompass a variety of stages in the drug discovery process, from assay development and validation to hit identification and in vivo pharmacology, catering to the needs of pharmaceutical and biotech companies globally.

Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

ViOptix, Inc. specializes in tissue oximetry technology that measures local tissue oxygen saturation. The company offers the T.Ox Tissue Oximeter, a portable unit featuring a color LCD touchscreen, which can operate with one or two channels and supports up to two fiber optic sensors. Its product line also includes Wi-Fi enabled T.Ox Remote Monitoring devices for wireless data transmission, one-time use T.Ox Small Patch sensors for continuous StO2 monitoring, and T.Ox Silicone Surround sensors for monitoring new flap applications. ViOptix's technology has applications across various fields, including plastic surgery, intraoperative and postoperative monitoring, wound healing assessment, detection of peripheral vascular disease, and critical care. Founded in 1999 and headquartered in Fremont, California, the company was previously known as Photonify Technologies, Inc. before rebranding in 2003. Its first product, the ODISsey System, received FDA clearance in 2005 for measuring localized tissue oxygenation in critical care settings.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Serica Technologies, Inc. is a medical device company based in Medford, Massachusetts, specializing in biodegradable, silk-based biomaterial platforms designed for tissue repair. The company develops a range of products, including SeriGel, a bioresorbable silk hydrogel used in plastic and reconstructive surgery, and the SeriFascia surgical scaffold implant, which aids in restoring functional collagen tissue lost due to surgery or aging. Additionally, Serica offers the SeriACL graft for anterior cruciate ligament repair, the SeriCuff scaffold for rotator cuff tendon repair, and the SeriScaffold surgical mesh for the repair of damaged connective tissues. These innovative products serve various applications in orthopedics, sports medicine, and aesthetic and reconstructive plastic surgery. Originally founded as Tissue Regeneration, Inc. in 1998, the company rebranded in 2006 and has since operated as a subsidiary of Allergan Inc.

ViOptix, Inc. specializes in tissue oximetry technology that measures local tissue oxygen saturation. The company offers the T.Ox Tissue Oximeter, a portable unit featuring a color LCD touchscreen, which can operate with one or two channels and supports up to two fiber optic sensors. Its product line also includes Wi-Fi enabled T.Ox Remote Monitoring devices for wireless data transmission, one-time use T.Ox Small Patch sensors for continuous StO2 monitoring, and T.Ox Silicone Surround sensors for monitoring new flap applications. ViOptix's technology has applications across various fields, including plastic surgery, intraoperative and postoperative monitoring, wound healing assessment, detection of peripheral vascular disease, and critical care. Founded in 1999 and headquartered in Fremont, California, the company was previously known as Photonify Technologies, Inc. before rebranding in 2003. Its first product, the ODISsey System, received FDA clearance in 2005 for measuring localized tissue oxygenation in critical care settings.